Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring

Shinya Abe1,2, Gaku Inoue1,2, Satoru Yamada1,3, Junichiro Irie1,3, Hiroyuki Nojima2, Kaoru Tsuyusaki2, Kensuke Usui2, Koichiro Atsuda2, Toshikazu Yamanouchi41Diabetes Center, Kitasato Institute Hospital, 2Center for Clinical Pharmacy and Clinical Sciences, Kitasato University, 3Department of Interna...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abe S, Inoue G, Yamada S, Irie J, Nojima H, Tsuyusaki K, Usui K, Atsuda K, Yamanouchi T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/78ab0254b54545f09cc7a8c044ad71cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:78ab0254b54545f09cc7a8c044ad71cb
record_format	dspace
spelling	oai:doaj.org-article:78ab0254b54545f09cc7a8c044ad71cb2021-12-02T01:42:04ZTwo-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring1178-7007https://doaj.org/article/78ab0254b54545f09cc7a8c044ad71cb2011-07-01T00:00:00Zhttp://www.dovepress.com/two-way-crossover-comparison-of-insulin-glargine-and-insulin-detemir-i-a7866https://doaj.org/toc/1178-7007Shinya Abe1,2, Gaku Inoue1,2, Satoru Yamada1,3, Junichiro Irie1,3, Hiroyuki Nojima2, Kaoru Tsuyusaki2, Kensuke Usui2, Koichiro Atsuda2, Toshikazu Yamanouchi41Diabetes Center, Kitasato Institute Hospital, 2Center for Clinical Pharmacy and Clinical Sciences, Kitasato University, 3Department of Internal Medicine, Keio University School of Medicine, 4Department of Internal Medicine, University of Teikyo School of Medicine, Tokyo, JapanObjective: This study aimed to compare the glucose-lowering effect and glycemic variability of insulin glargine with those of insulin detemir.Material and methods: This was an open-label, single-center, randomized, two-way crossover study in patients with diabetes on basal-bolus insulin therapy, with neutral protamine Hagedorn (NPH) insulin as basal insulin. Patients switched from NPH insulin to a course either of insulin glargine followed by insulin detemir, or insulin detemir followed by insulin glargine, continuing the same dose of the prior bolus of insulin. To evaluate the glucose-lowering effect, daily glycemic profiles were recorded for 72 hours by continuous glucose monitoring (CGM) in an outpatient setting. The mean amplitude of glycemic excursions, standard deviation (SD), and the mean of daily difference (MODD) were used to assess intraday and day-to-day glycemic variability.Results: Eleven patients were enrolled and nine completed the study. Mean blood glucose calculated from CGM values was significantly lower with insulin glargine compared with insulin detemir (9.6 &plusmn; 2.4 mmol/L versus 10.4 &plusmn; 2.8 mmol/L, P = 0.038). The SD was significantly lower with insulin glargine versus insulin detemir (2.5 &plusmn; 0.9 mmol/L vs 3.5 &plusmn; 1.6 mmol/L, P = 0.011). The MODD value was significantly lower with insulin glargine than with insulin detemir (2.2 &plusmn; 1.1 mmol/L vs 3.6 &plusmn; 1.7 mmol/L, P = 0.011). There was no significant difference between the two insulin analogs in terms of hypoglycemia.Conclusion: This study suggests that insulin glargine leads to more effective and more stable glycemic control than the same dose of insulin detemir.Keywords: continuous glucose monitoring, insulin detemir, insulin glargine&nbsp;Abe SInoue GYamada SIrie JNojima HTsuyusaki KUsui KAtsuda KYamanouchi TDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2011, Iss default, Pp 283-288 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Abe S Inoue G Yamada S Irie J Nojima H Tsuyusaki K Usui K Atsuda K Yamanouchi T Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
description	Shinya Abe1,2, Gaku Inoue1,2, Satoru Yamada1,3, Junichiro Irie1,3, Hiroyuki Nojima2, Kaoru Tsuyusaki2, Kensuke Usui2, Koichiro Atsuda2, Toshikazu Yamanouchi41Diabetes Center, Kitasato Institute Hospital, 2Center for Clinical Pharmacy and Clinical Sciences, Kitasato University, 3Department of Internal Medicine, Keio University School of Medicine, 4Department of Internal Medicine, University of Teikyo School of Medicine, Tokyo, JapanObjective: This study aimed to compare the glucose-lowering effect and glycemic variability of insulin glargine with those of insulin detemir.Material and methods: This was an open-label, single-center, randomized, two-way crossover study in patients with diabetes on basal-bolus insulin therapy, with neutral protamine Hagedorn (NPH) insulin as basal insulin. Patients switched from NPH insulin to a course either of insulin glargine followed by insulin detemir, or insulin detemir followed by insulin glargine, continuing the same dose of the prior bolus of insulin. To evaluate the glucose-lowering effect, daily glycemic profiles were recorded for 72 hours by continuous glucose monitoring (CGM) in an outpatient setting. The mean amplitude of glycemic excursions, standard deviation (SD), and the mean of daily difference (MODD) were used to assess intraday and day-to-day glycemic variability.Results: Eleven patients were enrolled and nine completed the study. Mean blood glucose calculated from CGM values was significantly lower with insulin glargine compared with insulin detemir (9.6 &plusmn; 2.4 mmol/L versus 10.4 &plusmn; 2.8 mmol/L, P = 0.038). The SD was significantly lower with insulin glargine versus insulin detemir (2.5 &plusmn; 0.9 mmol/L vs 3.5 &plusmn; 1.6 mmol/L, P = 0.011). The MODD value was significantly lower with insulin glargine than with insulin detemir (2.2 &plusmn; 1.1 mmol/L vs 3.6 &plusmn; 1.7 mmol/L, P = 0.011). There was no significant difference between the two insulin analogs in terms of hypoglycemia.Conclusion: This study suggests that insulin glargine leads to more effective and more stable glycemic control than the same dose of insulin detemir.Keywords: continuous glucose monitoring, insulin detemir, insulin glargine&nbsp;
format	article
author	Abe S Inoue G Yamada S Irie J Nojima H Tsuyusaki K Usui K Atsuda K Yamanouchi T
author_facet	Abe S Inoue G Yamada S Irie J Nojima H Tsuyusaki K Usui K Atsuda K Yamanouchi T
author_sort	Abe S
title	Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
title_short	Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
title_full	Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
title_fullStr	Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
title_full_unstemmed	Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
title_sort	two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/78ab0254b54545f09cc7a8c044ad71cb
work_keys_str_mv	AT abes twowaycrossovercomparisonofinsulinglargineandinsulindetemirinbasalbolustherapyusingcontinuousglucosemonitoring AT inoueg twowaycrossovercomparisonofinsulinglargineandinsulindetemirinbasalbolustherapyusingcontinuousglucosemonitoring AT yamadas twowaycrossovercomparisonofinsulinglargineandinsulindetemirinbasalbolustherapyusingcontinuousglucosemonitoring AT iriej twowaycrossovercomparisonofinsulinglargineandinsulindetemirinbasalbolustherapyusingcontinuousglucosemonitoring AT nojimah twowaycrossovercomparisonofinsulinglargineandinsulindetemirinbasalbolustherapyusingcontinuousglucosemonitoring AT tsuyusakik twowaycrossovercomparisonofinsulinglargineandinsulindetemirinbasalbolustherapyusingcontinuousglucosemonitoring AT usuik twowaycrossovercomparisonofinsulinglargineandinsulindetemirinbasalbolustherapyusingcontinuousglucosemonitoring AT atsudak twowaycrossovercomparisonofinsulinglargineandinsulindetemirinbasalbolustherapyusingcontinuousglucosemonitoring AT yamanouchit twowaycrossovercomparisonofinsulinglargineandinsulindetemirinbasalbolustherapyusingcontinuousglucosemonitoring
_version_	1718402902810165248

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring

Ejemplares similares